Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($28.1B)

Statische Daten (Echtzeitfinanzen werden geladen…)

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

Lieferkettenbeziehungen

Wettbewerber

Pfizer Inc.

Antiviral therapies

Auswirkung: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

Auswirkung: Competing in oncology

Partner

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

Auswirkung: Research partnership

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Gilead Sciences, Inc..

Unternehmensinformationen

Hauptsitz

Foster City, California, USA

Gegründet

1987

Mitarbeiter

18,000+

Website

gilead.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten